They are certainly not making it easy to keep holding. The lack of new news is making it easy to question certain assumptions. In particular why was Cogstate not used for the market surveillance for Leqembi and where will Cognigram fit in to the clinical diagnostic pathway for AD. I think there are good answers for both but they are reasonable questions. In particular as there is currently no reimbursement in the US, for digital cognitive tests in AD, how much of the diagnostic purse will Cognigram be able to capture in the near term.
All of that said Lilly progress with the FDA is due soon and that should bring plenty of news attached with it, I am assuming approval.
CGS Price at posting:
$1.41 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)